Demonstrated sustained efficacy at 4 years
In the fourth year after vaccination, VE against shingles in patients:
- ≥50 years was 93.1% vs. placebo (95% CI: 81.2, 98.2).1†
- ≥70 years was 87.9% vs. placebo (95% CI: 73.3, 95.4).1, 3‡
Duration of protection beyond 4 years is currently under investigation.
* Pooled results of two multi-centre, randomized, observer-blind, placebo-controlled trials in subjects 50 years of age and older who received doses of SHINGRIX (n=14,645) or placebo (n=14,660) at 0 and 2 months. Primary efficacy analysis was of the Modified Total Vaccinated Cohort (mTVC): all subjects randomized who received a second dose of the vaccine and did not develop a confirmed case of shingles within one month after the second dose. Randomization was stratified by age in years: 50–59, 60–69, 70–79 and ≥80 in an 8:5:3:1 ratio. Subjects were followed for the development of shingles for a median of 3.1 years (ZOE-50; range: 0–3.7 years) and 3.9 years (ZOE-70; range: 0–4.5 years). Primary endpoint was vaccine efficacy as measured by the reduction in herpes zoster risk.
†Data from ZOE-50; vaccine efficacy (VE) adjusted by region.
‡Pooled data from ZOE-50 and ZOE-70; vaccine efficacy (VE) adjusted by region.
- SHINGRIX Product Monograph. GlaxoSmithKline Inc., October 13, 2017.
- Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372(22):2087-96.
- Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016 Sep;375(11):1019-32.